

Effect of onset-to-admission time and care bundle achievement on functional outcomes in patients with ICH: a population-based study

Manuscript Number: WNL-2025-201784R2

Authors:

Álvaro Lambea-Gil^{1,2,3}; Joan Marti-Fabregas^{1,2,3}; Pere Cardona⁴; David Rodriguez-Luna^{3,5,6}; Mónica Millán^{7,8}; Sergi Amaro^{10,9}; Luis Prats-Sanchez^{1,2}; Yolanda Silva^{11,12}; Laia Seró¹³; Ana Rodriguez-Campello¹⁴; David Cánovas¹⁵; Alejandro Martinez-Domeño^{1,2}; Marina Guasch-Jiménez^{1,2}; Garbiñe Ezcurra-Díaz^{1,2}; Jara Carcel-Marquez¹⁶; Israel Fernandez-Cadenas¹⁶; Natalia Pérez De La Ossa^{17,18}; Sònia Abilleira¹⁸; Mercè Salvat-Plana^{19,20,21}; Olga Fagundez^{17,19}; Pol Camps-Renom^{1,2}; Anna Ramos-Pachón^{1,2,3}

1. Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau
2. Institut de Recerca Sant Pau (IR SANT PAU)
3. Department of Medicine, Universitat Autònoma de Barcelona
4. Stroke Unit, Department of Neurology, Hospital Universitari de Bellvitge
5. Stroke Unit, Department of Neurology, Hospital Universitari Vall d'Hebron
6. Stroke Research Group, Vall d'Hebron Research Institute
7. Neurology Service, Neurosciences Department, Hospital Germans Trias i Pujol
8. Germans Trias i Pujol Research Institute (IGTP)
9. Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic de Barcelona
10. Institut d'Investigacions Biomèdiques August Pi i Sunyer
11. Department of Neurology, Hospital Universitari Dr. Josep Trueta
12. Department of Medicine, Universitat de Girona
13. Stroke Unit, Department of Neurology, Hospital Universitari Joan XXIII de Tarragona
14. Stroke Unit, Department of Neurology, Hospital Del Mar
15. Stroke Unit, Department of Neurology, Hospital Universitari Parc Taulí
16. Pharmacogenomics and Neurovascular Genetics Research Group, Institut de Recerca Sant Pau (IR SANT PAU)
17. Stroke Unit, Neurology Service, Hospital Universitari Germans Trias i Pujol
18. Stroke Programme, Health Department of Catalonia
19. Agency for Health Quality and Assessment of Catalonia
20. Pla director de les malalties vasculars cerebrals
21. CIBER Epidemiology and Public Health

Corresponding Author: Anna Ramos-Pachón

Group Authorship: Yes. All members of the study group qualify as authors

Group Name: HIC-CAT

Contributions:

Álvaro Lambea-Gil: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data; Joan Marti-Fabregas: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Pere Cardona: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; David Rodriguez-Luna: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Mónica Millán: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Sergi Amaro: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Luis Prats-Sanchez: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Yolanda Silva: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Laia Seró: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Ana Rodriguez-Campello: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; David Cánovas: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Alejandro Martinez-Domeño: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Marina Guasch-Jiménez: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Garbiñe Ezcurra-Díaz: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Jara Carcel-Marquez: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data; Israel Fernandez-Cadenas: Drafting/revision of the manuscript for content, including medical writing for content; Natalia Pérez De La Ossa: Drafting/revision of the manuscript for content, including medical writing for content; Sònia Abilleira: Drafting/revision of the manuscript for content, including medical writing for content; Mercè Salvat-Plana: Drafting/revision of the manuscript for content, including medical writing for content; Olga Fagundez: Drafting/revision of the manuscript for content, including medical writing for content; Pol Camps-Renom: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data; Anna Ramos-Pachón: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data;

Abstract: Background and Objectives: Intracerebral hemorrhage (ICH) remains a leading cause of morbidity and mortality, with limited effective treatments. Early implementation of a care bundle protocol (CBP) within 6h of symptom onset has been shown to improve functional outcomes, although its effect beyond this time frame remains unclear. We assessed the impact of onset-to-admission (OTA) time and CBP achievement on functional outcome and mortality in patients with acute spontaneous ICH. Methods: We conducted a population-based study of a prospective cohort of consecutive patients diagnosed with acute spontaneous ICH between 2020 and 2022 in Catalonia, Spain. Inclusion criteria were patients aged {greater than or equal to} 18 years, OTA time <24h, and a baseline modified Rankin Scale (mRS) score {less than or equal to} 3. CBP achievement was defined as attaining control in the first 24h of blood pressure (<140/90 mmHg), glycemia (<150 mg/dL), body temperature (<37.5 °C), blood oxygen saturation (>92%) and, if required, anticoagulation reversal. The primary outcome was the proportion of patients with a favorable functional outcome, defined as mRS {less than or equal to} 3 at 3-month follow-up. The effects of OTA time and CBP achievement on outcomes were evaluated using multivariable logistic regression. Potential interaction between OTA time and CBP achievement was assessed using the likelihood-ratio test. Results: A total of 1,821 patients were included (mean age 70.3 {plus minus} 14.1 years, 37.7% women). CBP was achieved in 27.7% of patients. Shorter OTA time was independently associated with poorer functional outcome (aORx1h 1.04, 95% CI 1.02-1.06). CBP achievement was associated with a higher probability of favorable outcome at 3 months (aOR 1.66, 95% CI 1.29-2.15). An interaction between OTA time and CBP achievement was observed (p=0.016), indicating greater CBP benefits for earlier admission. This interaction was evident up to 13.8h post-symptom onset, with the CBP benefit concentrated in the first 8h. Discussion: Our findings highlight the importance of timely CBP application to improve functional outcome in patients with ICH, even beyond the first 6h after symptom onset. While earlier intervention remains ideal, our results support expanding CBP implementation and promoting "Code ICH" initiatives to enhance patient outcomes in stroke care systems. Clinical Trials Registration (Optional): ClinicalTrials.gov identifier: NCT03956485

Effect of onset-to-admission time and care bundle achievement on functional outcomes in patients with intracerebral hemorrhage: a population-based study

Short title: Onset-to-admission and care bundle achievement on ICH functional outcomes.

Key Words: Intracerebral hemorrhage, Neurocritical care, Acute stroke management, Care Bundle, Time-to-Admission

ABSTRACT

Background and Objectives: Intracerebral hemorrhage (ICH) remains a leading cause of morbidity and mortality, with limited effective treatments. Early implementation of a care bundle protocol (CBP) within 6h of symptom onset has been shown to improve functional outcomes, although its effect beyond this time frame remains unclear. We assessed the impact of onset-to-admission (OTA) time and CBP achievement on functional outcome and mortality in patients with acute spontaneous ICH.

Methods: We conducted a population-based study of a prospective cohort of consecutive patients diagnosed with acute spontaneous ICH between 2020 and 2022 in Catalonia, Spain. Inclusion criteria were patients aged ≥ 18 years, OTA time < 24 h, and a baseline modified Rankin Scale (mRS) score ≤ 3 . CBP achievement was defined as attaining control in the first 24h of blood pressure ($< 140/90$ mmHg), glycemia (< 150 mg/dL), body temperature (< 37.5 °C), blood oxygen saturation ($> 92\%$) and, if required, anticoagulation reversal. The primary outcome was the proportion of patients with a favorable functional outcome, defined as mRS ≤ 3 at 3-month follow-up. The effects of OTA time and CBP achievement on outcomes were evaluated using multivariable logistic regression. Potential interaction between OTA time and CBP achievement was assessed using the likelihood-ratio test.

Results: A total of 1,821 patients were included (mean age 70.3 ± 14.1 years, 37.7% women). CBP was achieved in 27.7% of patients. Shorter OTA time was independently associated with poorer functional outcome (aOR_{x1h} 1.04, 95% CI 1.02-1.06). CBP achievement was associated with a higher probability of favorable outcome at 3 months (aOR 1.66, 95% CI 1.29-2.15). An interaction between OTA time and CBP achievement was observed ($p=0.016$), indicating greater CBP benefits for earlier admission. This interaction was evident up to 13.8h post-symptom onset, with the CBP benefit concentrated in the first 8h.

Discussion: Our findings highlight the importance of timely CBP application to improve functional outcome in patients with ICH, even beyond the first 6h after symptom onset. While earlier intervention remains ideal, our results support expanding CBP implementation and promoting "Code ICH" initiatives to enhance patient outcomes in stroke care systems.

Trial Registration Information: ClinicalTrials.gov identifier: NCT03956485

Classification of Evidence: This study provides Class III evidence that in patients with acute intracerebral hemorrhage, achievement of a standardized care bundle protocol is associated with better functional outcomes at 3 months.

INTRODUCTION

With nearly 3.5 million new cases worldwide each year, intracerebral hemorrhage (ICH) remains the type of stroke with the highest morbidity and mortality rates (1). This scenario has remained unchanged for decades, likely due to a lack of effective treatments (2).

Despite prior inconsistent findings in patients with ICH (3,4), the INTERACT3 trial (5) demonstrated that implementing a care bundle protocol (CBP) in the first 6h after symptom onset – early control of high blood pressure and management of hyperglycemia, fever, and abnormal coagulation – significantly improves functional outcomes in patients with acute spontaneous ICH. Furthermore, the INTERACT4 trial (6) underscored the benefits of early intervention in patients with ICH, showing that lowering prehospital blood pressure is associated with better outcomes. Together, these findings highlight the critical role of timely medical management in ICH (7).

A shorter time from symptom onset to hospital admission is also known to be an independent factor for hematoma expansion (8,9) and poorer outcomes (10), likely reflecting the dynamic phase of early-stage active bleeding and the greater clinical severity of these patients. The fact that the “Code ICH” initiative (7, 11) – based on INTERACT3 results – currently emphasizes treatment within the first 6h post-symptom onset, could inadvertently perpetuate therapeutic nihilism in the management of patients presenting beyond this time frame (12). While CBP has also shown some benefits in reducing mortality in acute patients (13), data on its implementation and effect on functional outcomes at extended time intervals remain scarce. Nevertheless, reducing onset-to-admission (OTA) time should stand as a primary goal for stroke code programs, facilitating faster diagnosis and tailored management. Given the findings of recent trials (5,6), we wonder whether time could emerge as a new ally in acute ICH, or whether it remains a challenge to overcome.

Our aims with this population-based study were as follows: 1) to ascertain whether a reduced OTA time is associated with better functional outcomes in patients with acute spontaneous ICH who achieve CBP within the first 24h; 2) to assess CBP achievement according to OTA time; and 3) to explore whether the benefits of CBP for functional outcomes are influenced by OTA time.

MATERIAL AND METHODS

Study design and population

We conducted an observational, multicenter study using a prospective population-based cohort of patients consecutively diagnosed with acute spontaneous ICH over a 2-year period (from March 2020 to March 2022) in Catalonia, Spain (HIC-CAT study) (14).

The HIC-CAT study included all patients aged ≥ 18 years diagnosed with spontaneous ICH in Catalan public hospitals with stroke care capacity. Based on stroke resources, participating hospitals – all audited by the Catalan Agency for Health Quality and Assessment (AQUAS) – were classified as Comprehensive Stroke Centers (CSC, n=9), Primary Stroke Centers (PSC, n=5), or Telestroke Centers (TSC, n=14). CSCs met structural, staffing, and diagnostic criteria for 24/7

specialized care in ICH, including neurosurgery on-site, while PSCs lacked neurosurgical capacity, and TSCs relied on remote neurology support. More details on the Catalan Stroke System and hospital organization are provided in the main HIC-CAT report (14). Although no unified protocol for ICH management existed, centers adhered to available European Stroke Organization (15) and American Heart Association (16) guidelines. During the study period, each center followed its usual care pathway for patients with ICH. In general, blood pressure was managed with the goal of achieving values <140/90 mmHg, typically using intravenous antihypertensive agents. Anticoagulation reversal was performed based on the type of anticoagulant used, with centers having access to prothrombin complex concentrate, vitamin K, and idarucizumab, among other options. For patients on vitamin K antagonists, reversal was indicated for an INR above 1.3. All centers had access to neurosurgical consultation, either on-site or remote. Pre-hospital blood pressure management was not routinely implemented, and only applied in selected hypertensive emergencies managed by advanced life support units

Some patients were transferred between hospitals, but all were included in the analysis, and time intervals were calculated from symptom onset to arrival at the first hospital, which marked the beginning of acute care.

Standard Protocol Approvals, Registrations, and Patient Consents

The HIC-CAT (ClinicalTrials.gov identifier: NCT03956485) study was approved by the ethics committee of Hospital de la Santa Creu i Sant Pau as the sponsoring center (IIBSP-HIC-2019-22) and locally by each participating center. Patients or their legal representatives provided informed consent to participation. In some hospitals, ethics committees required consent only for stroke survivors and for authorization of the 3-month follow-up assessments via telephone interview.

Inclusion and Exclusion Criteria

For the present post hoc analysis, we included patients aged ≥ 18 years diagnosed with spontaneous ICH in the emergency departments of all Catalan public hospitals with stroke care capacity. Exclusion criteria were patients with OTA time ≥ 24 h and those with a baseline modified Rankin Scale (mRS) score >3 . Patients lacking critical data on time metrics or follow-up were also excluded (Figure 1). The reporting of this study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (17).

Study variables

As described in the main HIC-CAT report (14), the following variables were collected for all patients: 1) demographics: age and sex; 2) past medical history: baseline mRS score, vascular risk factors, and use of antithrombotic agents; 3) logistics and time metrics: type of stroke center, OTA time and admission-to-neuroimaging time; 4) clinical and radiological findings on admission: National Institutes of Health Stroke Scale (NIHSS) and Glasgow Coma Scale (GCS) scores, ICH volume, location (lobar, deep, or infratentorial), and presence of an intraventricular hemorrhage (IVH) component; 5) treatment targets at 24h: blood pressure, glycemia, body temperature, blood oxygen saturation, and anticoagulation reversal; 6) neurosurgery consultation and intervention; 7) in-hospital complications; and 8) 3-month functional outcome

and mortality. Hemorrhage volume was quantified by the ABC/2 formula or planimetry on computed tomography, according to usual local neuroradiology protocol.

Symptom onset was determined using the last-time-seen-well approach, classifying patients into two groups: those with a known onset time and those with wake-up strokes or unknown onset. The OTA time, defined as the time from symptom onset to first hospital admission, was analyzed both as a continuous variable and across categorized time frames (<2h, 4h, 6h, 8h, 10h, 12h and 24h).

CBP achievement was defined as meeting, at any time within the first 24h, all pre-specified goals as follows: 1) blood pressure <140/90 mmHg; 2) glycemia <150 mg/dL; 3) body temperature <37.5 °C; 4) blood oxygen saturation >92%; and 5) anticoagulation reversal if required (13, 15, 16). To assess outcomes, any pre-specified goal for which data were missing was considered as not achieved.

Primary and secondary outcomes

Our primary outcome was the proportion of patients achieving a favorable (mRS 0-3) versus unfavorable (mRS 4-6) functional outcome at 3 months. The secondary outcome was 3-month mortality. Outcomes were centrally assessed by blinded certified evaluators using a validated methodology (18).

Statistical analysis

Continuous descriptive variables were reported as means and standard deviations (SD), and if not normally distributed (as tested by histograms or the Shapiro-Wilk normality test), as medians and interquartile ranges (IQR). Categorical variables were expressed as counts and percentages. Bivariable analyses comparing groups were performed using the Student's t-test or the Mann-Whitney U test (when a nonparametric test was required) for continuous variables, and the χ^2 test for categorical variables.

The primary outcome was analyzed using logistic regression, calculating unadjusted odds ratio (OR) and adjusted OR (aOR) values with their 95% confidence intervals (CI). Adjustment variables were selected as follows: starting with a maximal model that included CBP achievement and all variables that were statistically significant ($p < 0.05$) in the univariable analysis (divided by two subgroups: 3-month mRS ≤ 3 and 3-month mRS > 3), we performed permutations and combinations of all possible models. The best model was selected, ensuring good model fit and parsimony, according to area under the curve (AUC) and Akaike information criterion (AIC) scores. The final model was adjusted for age, baseline mRS score, NIHSS score on admission, ICH volume, IVH component, and infratentorial location (all well-known predictors of ICH outcomes) (16). A collinearity analysis was performed among these adjustment variables, confirming the absence of collinearity. Following a complete-case analysis approach and given the low proportion of missing data (<10%), patients whose data for key adjustment variables were missing were excluded from the analysis.

We performed an exploratory mediation analysis to assess the effect of each CBP component on the primary outcome.

Interaction between CBP achievement and OTA time was tested using a likelihood-ratio test. A binomial logistic regression model was developed to predict the 3-month favorable functional outcome, explained by CBP achievement (binary variable), OTA time (continuous variable) and the interaction of the two variables in our dataset. Predictions were obtained in the same sample on the link scale, and the inverse logit transformation was applied to derive predicted probabilities with 95% CI. The CI for each group (CBP achievement no vs. yes) was compared at corresponding time points to assess overlap. The association of CBP achievement with 3-month favorable functional outcome was additionally studied in 2h OTA interval windows and adjusted by the same variables of final model to assess the CBP effects over time.

A similar approach was used for the secondary outcome, with the final multivariable logistic regression model adjusted for the same variables as the primary outcome. The interaction between CBP achievement and OTA time for 3-month mortality was assessed using the same methodology.

Sensitivity analyses were conducted for primary and secondary outcomes, excluding patients with unknown symptom onset, active anticoagulation treatment, and withdrawal of care (WoC) within the first 24h. We also evaluated CBP achievement and functional outcomes based on the type of center providing initial medical care, categorized as either a CSC or PSC/TSC.

Statistical significance for all analyses was set at $p < 0.05$ (2-sided). All analyses were performed using Stata v.17 (StataCorp, College Station, TX, USA). Forest plots and interaction figure between CBP achievement and OTA interval were plotted using R v.4.3.2 (RStudio, Boston, MA, USA).

Data availability

Anonymized data not published within this article may be shared upon reasonable request to any qualified investigator.

RESULTS

A total of 1,821 patients were included in this study (Figure 1), mean age 70.3 (± 14.1) years, and 37.7% ($n=687$) women. Symptom onset was known for 66.2% of patients ($n=1,205$) and the median OTA time was 95 (58-186) minutes. Median baseline NIHSS score was 13 (5-21), median hematoma volume was 17.5 (5.8-45) mL, and IVH was present in 38.6% of patients ($n=703$) (eTable 1).

The CBP goals were achieved by 27.7% of patients ($n=504$), a proportion that increased to 31.8% after excluding those with WoC within the first 24h (20.9%, $n=355$). Achievement of each pre-specified CBP goal was as follows: body temperature, 91.9%; blood oxygen saturation, 91.3%; glycemia, 79.2%; anticoagulation reversal (if required), 77.5%; and blood pressure, 50.6%.

Influence of onset-to-admission time on functional outcome and mortality

Table 1 shows patient characteristics according to OTA time, stratified by OTA ≤ 6 h ($n=1294$, 71.1%) and > 6 h ($n=527$, 28.9%). Patients admitted within the first 6h were younger, had a better baseline mRS, higher NIHSS score and blood pressure on admission, and were more likely to have deep ICH.

Patients with a favorable outcome (mRS 0-3) at 3 months (eTable 1) were more likely to achieve the CBP goals and had longer OTA time. Table 2 reports variables independently associated with a favorable outcome in the multivariable analysis, along with their strength of association. A shorter OTA time was associated with an unfavorable outcome (aOR_{x1h} 1.04, 95% CI 1.02-1.06), a finding that remained consistent in sensitivity analyses evaluating patients with known (aOR_{x1h} 1.09, 95% CI 1.05-1.14) and unknown (aOR_{x1h} 1.06, 95% CI 1.02-1.10) symptom onset. Additionally, a shorter OTA time was independently associated with higher 3-month mortality (aOR_{x1h} 0.98, 95% CI 0.95-0.99). After excluding patients with WoC within the first 24h, the association between shorter OTA time and unfavorable functional outcome (mRS >3) persisted, but the association with 3-month mortality was no longer statistically significant (aOR_{x1h} 0.98, 95% CI 0.96-1.01, $p = 0.226$).

Effect of care bundle protocol achievement on functional outcome and mortality

Table 3 summarizes the characteristics of patients according to CBP achievement. Patients who achieved the CBP goals were younger, had a lower NIHSS score on admission and were more likely to arrive at a CSC. The CBP goals were met by 342 patients (26.4%) with an OTA ≤ 6 h and by 162 patients (30.7%) with an OTA > 6 h ($p=0.062$).

For the entire cohort, CBP achievement was independently associated with a favorable outcome (aOR 1.66, 95% CI 1.29-2.15) (Table 2). For patients with known symptom onset, this association persisted (aOR 1.98, 95% CI 1.44-2.73). However, for patients with unknown symptom onset, CBP achievement was only associated with favorable outcomes in patients not taking prior anticoagulation therapy ($n=430$, 76.5%; aOR 1.89, 95%CI 1.07-3.33).

In an exploratory analysis, we assessed the individual contribution of each CBP component on the primary outcome, and the results are presented in Supplementary eTable 2. Importantly, the greatest effect size was shown for oxygen saturation and glycemia control.

Regarding the type of stroke center providing initial medical care, 31.3% of patients arriving at a CSC achieved the CBP goals, compared to 20.3% of patients arriving at a PSC/TSC ($p<0.001$). Using the same model as for the primary outcome and after adjusting for confounders, initial care at a CSC was associated with higher odds of meeting the CBP goals (aOR 1.97, 95% CI 1.55-2.52). Nevertheless, stroke center type did not independently affect the 3-month mRS outcome (aOR 0.85, 95% CI 0.66-1.10, $p=0.211$). Regarding acute ICH care, 388 patients (22.2%) were not admitted to any specialized critical care unit (Stroke Unit or Intensive Care Unit). This proportion was higher among patients initially admitted to PSCs/TSCs (33%) compared to those admitted to CSCs (17.2%, $p<0.001$). Of those admitted to a specialized unit, 31.6% achieved CBP goals, compared to 18.3% among patients who were not ($p< 0.001$). These differences remained significant after excluding WoC cases.

Hematoma expansion within the first 72 hours was observed in 256 patients (14.06%). In a sensitivity analysis including hematoma expansion in the multivariable model, both OTA time and CBP achievement remained independently associated with 3-month functional outcome.

Concerning 3-month mortality, CBP achievement was associated with reduced risk of death, although this did not reach statistical significance (aOR 0.78, 95% CI 0.60-1.01, $p=0.061$). This was consistent among patients with known symptom onset (aOR 0.73, 95% CI 0.52-1.03, $p=0.070$) and significant in patients with unknown onset not taking anticoagulation therapy

(n=430, 76.5%; aOR 0.48, 95% CI 0.27-0.85). After excluding WoC cases, the association between CBP achievement and mortality remained non-significant (aOR 0.79, 95% CI 0.59-1.06, p=0.112).

Interaction between onset-to-admission time and care bundle protocol achievement

An interaction was observed between OTA time and CBP achievement in the adjusted logistic regression model for 3-month functional outcome (p=0.016), indicating that earlier arrival enhanced the effect of CBP. This interaction persisted up to 13.8h after symptom onset (Figure 2). When included in the adjusted model, CBP achievement had a stronger impact on the probability of a favorable functional outcome (aOR 1.97, 95% CI 1.47-2.63). This effect was consistent across all time frames and particularly pronounced in patients admitted within the first 12 hours (aOR 2.08, 95% CI 1.49-2.89). Notably, this association was primarily driven by early arrivals, as adjusted sensitivity analyses showed significant effects only for the <2h, 2-4h, 4-6h, and 6-8h intervals (Figure 3).

Regarding 3-month mortality, no interaction was observed between OTA time and CBP achievement in the adjusted model (p=0.901). Likewise, sensitivity analyses across different time frames revealed no association.

Effect of onset-to-admission time in patients who achieved care bundle goals

For the patients who achieved CBP goals (n=504, 27.7%), Table 4 summarizes details of the multivariable analysis of variables independently associated with a favorable 3-month functional outcome, along with their strength of association. A shorter OTA time was no longer associated with unfavorable outcome (aOR_{x1h} 1.01, 95% CI 0.97-1.05, p=0.570), nor with greater 3-month mortality (aOR_{x1h} 0.98, 95% CI 0.94-1.03, p=0.430).

Classification of Evidence: This study provides Class III evidence that in patients with acute intracerebral hemorrhage, achievement of a standardized care bundle protocol is associated with better functional outcomes at 3 months.

DISCUSSION

Our population-based study of patients with spontaneous ICH highlights the positive effect on functional outcomes of CBP implementation in the first 24h post-symptom onset. CBP achievement in this time frame was independently associated with better functional outcome at 3 months. The interaction observed between CBP achievement and OTA time emphasizes that the CBP benefits are greater the sooner the patients reach the hospital, supporting the need for timely CBP application.

Compared to the INTERACT3 trial, our study presents notable differences. In INTERACT3, only 0.9% of patients were on oral anticoagulants and 10.4% had diabetes, whereas in our cohort, these figures reached 19.2% and 25%, respectively, indicating a population with greater clinical complexity and higher risk of poor outcomes. In addition, our CBP included oxygen saturation as a predefined target from the acute phase, reflecting a broader physiological optimization strategy. Structural and systemic differences between settings also warrant consideration. While INTERACT3 was conducted primarily in low- and middle-income countries and implemented CBP in hospitals without prior standardized protocols, our study took place in Catalonia (Spain), a high-income region with a mature, integrated stroke network. Although no

unified ICH-specific protocol was in place across centers, all adhered to international guidelines (15, 16), and CBP targets were clearly defined. Despite these favorable conditions, only 27.7% of patients achieved full CBP implementation in our cohort. Similar challenges have been reported in other high-income countries, such as Germany and Italy, where real-world data reveal persistent barriers to implementing CBP targets, even in well-resourced environments (25, 26). Nevertheless, our findings are consistent with those of INTERACT3 in demonstrating the benefit of CBP implementation. The fact that CBP goal achievement remained independently associated with favorable outcomes, even in a high-income and real-world setting, reinforces the generalizability of their results. Importantly, our experience highlights that having access to protocols is not sufficient; alignment with emerging high-quality evidence, sustained clinical adherence, and the adoption of key performance indicators (KPIs) are essential to translate protocolized care into improved outcomes.

Shorter times to ICH diagnosis or admission have traditionally been associated with poorer outcomes (8-10). Interestingly, in our study the prognostic impact of a shorter OTA time was mitigated when CBP was achieved. In essence, CBP achievement appears to counteract the negative effect of early hospital admission, demonstrating the transformative potential of early intervention in acute ICH management. This finding, which challenges the conventional understanding of time in ICH prognosis (10), suggests that timely CBP application could alter the natural course of the disease and become a cornerstone of effective management. Early and systematic implementation of these measures could optimize outcomes, regardless of patient-specific characteristics (19, 20).

In our cohort, the CBP effect persisted for up to 14h, and after adjustment for covariates, was particularly evident in the first 8h. Although our data may suggest that CBP efficacy diminishes beyond this time frame, it is important to note that CBP does not become entirely ineffective; merely that the effect is substantially reduced. A larger sample for the 8-24h window is needed to further clarify these results. Given these findings, we align with calls for the establishment of a "Code ICH" (7, 11). However, we advocate for a time window extending beyond the first 6h reported by the INTERACT3 trial (5), recommending a window encompassing the first 24h, as already implemented in acute ischemic stroke protocols. Our results not only underscore the importance of early intervention, but also reinforce the pivotal role of CBP implementation for all acute ICH cases where timely intervention is feasible.

Such an approach would facilitate early recognition, rapid transport, and prompt initiation of CBP at any available hospital, without waiting for specialized care at a CSC, where surgical interventions may be considered (21). However, in our cohort study that included all types of stroke centers in Catalonia, achieving CBP was challenging, as only 27.7% met all pre-specified CBP goals. Leaving aside the potential impact of a longstanding therapeutic nihilism regarding ICH, this low rate may be partially explained by 1) the underutilization of specialized critical care units (up to 22.2% of patients did not receive this care), and 2) limited motivation for rapid and sustained control of CBP parameters at the time of the HIC-CAT study, as recruitment for this study took place before the INTERACT3 and INTERACT4 trials had consistently demonstrated the positive effect of medical treatment on functional outcomes. Nevertheless, it is important to note that, even in those trials and in other observational studies, many patients failed to meet CBP goals (particularly regarding blood pressure) (5, 6, 19).

In addition, although CBP was originally designed and tested as an all-or-none strategy in the INTERACT3 trial, our post hoc exploratory analysis suggests that certain components may contribute more strongly to its impact. In our cohort, this was driven by oxygen saturation and glycemic control. Notably, the effect on functional outcome was significant when at least four of the five CBP targets were achieved, suggesting a cumulative and potentially synergistic effect. These findings reinforce the rationale behind bundled care strategies, where the combined implementation of multiple interventions likely drives the overall benefit. Furthermore, when we assessed whether the effect of OTA time and CBP were mediated solely through the prevention of hematoma expansion, both variables remained independently associated with functional outcomes. This suggests that early arrival may influence prognosis through multiple pathways: not only by increasing the risk of hematoma growth, but also by contributing to other early complications (24). Similarly, the protective effect of CBP likely extends beyond hematoma stabilization alone.

While the center type did not significantly affect prognosis, as already reported in the main HIC-CAT report (14), CBP achievement was lower for PSC/TSC (20.3%) compared to CSC (31.3%), underlining the importance of establishing well-coordinated care networks to enable CBP implementation across all hospitals. Mobile stroke units could provide earlier treatment for patients in remote areas lacking rapid hospital access, but they are unaffordable for many stroke care systems (22). As for other strategies, such as direct transport to a CSC, these have shown no benefit for patients with ICH and may even cause harm (23, 24). Given the low technical requirements of CBP measures, allocating adequate resources, providing continuous training, and conducting regular re-evaluations of KPIs could improve adherence in centers where stroke physicians are not continuously available. This approach aligns with emerging evidence of the effectiveness of early intervention and emphasizes the need for enhanced prehospital and inter-hospital coordination to minimize treatment delays (6, 24). Ensuring timely access to any center that applies CBP should remain a priority until more effective prehospital solutions, such as blood-based biomarkers or other novel technologies, allow for the identification of patients with ICH, enabling CBP implementation even in the ambulance.

Strengths and limitations

The main strengths of this study lie in its large population-based sample, providing a real-world perspective on current ICH management within an experienced stroke network, and the fact that reliability was ensured by central blind assessment of functional outcomes by qualified evaluators. However, several limitations are acknowledged. As happens with all observational studies, there is a potential for reporting bias and unmeasured confounding, particularly regarding factors excluded from analysis that may affect patient outcomes. In particular, disentangling the effects of OTA and CBP achievement from underlying disease severity is inherently difficult, as both variables may reflect aspects of initial clinical status. Despite our efforts to adjust for relevant covariates, residual confounding cannot be excluded. “Due to missing follow-up and core clinical variables, 221 patients (10.1%) could not be included in the central registry database, limiting our ability to assess potential selection bias.”

In addition, although the study was based on prospectively collected data, the specific analyses assessing the effect of OTA time and CBP achievement on outcomes were post hoc in nature. As such, the findings should be interpreted with appropriate caution. Nevertheless, the prospective and consecutive enrollment of patients to some extent mitigates this limitation. Additionally,

stroke care organization can vary significantly across regions, and consequently, our findings specific to the Catalan healthcare system cannot be considered generalizable to areas where prehospital, PSC/TSC, and CSC systems are not well-integrated. Another limitation is that, although the participating centers adhered to clinical guidelines and documented CBP achievement, CBP was implemented in each center according to local adaptations that were not specifically recorded or pre-specified. As a result, and since treatment goals were not among the primary objectives of the HIC-CAT study, CBP timing, implementation method, and consistency in achieving goals remain unknown, and this variability may have influenced outcomes. Neurosurgical consultation – although available and performed in selected cases – was not included as a core component of the CBP, as vascular neurologists filtered the need for referral based on clinical and radiological criteria. While this reflects the structure of our stroke network, it differs from broader CBP definitions such as that used in INTERACT3 and may limit comparability across settings. The specific timing and reasons for WoC were also not assessed. Moreover, while our overall sample size was robust, the number of patients in the 8-24h window may have been insufficient to detect subtle differences in CBP efficacy during this period. Finally, the study focused on functional outcomes at 3 months, and therefore may not capture the long-term consequences of ICH.

Conclusions

In patients with ICH admitted within the first 24h after symptom onset, achieving CBP goals is associated with better outcomes, particularly among those treated within the first 8h. Notably, CBP achievement appears to mitigate the poorer outcomes typically associated with early hospital arrival, highlighting the transformative potential of a “Code ICH” initiative to improve the natural course of the disease, even in high-income countries. Future research should aim to optimize these strategies and assess their applicability across diverse healthcare systems, while integrating these protocols into ongoing studies on acute spontaneous ICH to promote a comprehensive approach to care.

Study funding

The HIC-CAT registry was supported by Fundació Ictus and Instituto de Salud Carlos III (ISCIII) through the RICORS-ICTUS network (RD21/0006/0006).

REFERENCES

1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol.* 2021;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0.
2. van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurol.* 2010;9(2):167-76. doi: 10.1016/S1474-4422(09)70340-0.

3. Moullaali TJ, Wang X, Martin RH, et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. *Lancet Neurol.* 2019;18(9):857-64. doi: 10.1016/S1474-4422(19)30196-6.
4. Moullaali TJ, Wang X, Sandset EC, et al; Blood Pressure in Acute Stroke (BASC) Investigators. Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. *J Neurol Neurosurg Psychiatry.* 2022;93(1):6-13. doi: 10.1136/jnnp-2021-327195.
5. Ma L, Hu X, Song L, et al. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. *Lancet.* 2023;402(10395):27-40. doi: 10.1016/S0140-6736(23)00806-1.
6. Li G, Lin Y, Yang J, et al; INTERACT4 Investigators. Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke. *N Engl J Med.* 2024;390(20):1862-72. doi: 10.1056/NEJMoa2314741.
7. Li Q, Yakhkind A, Alexandrov AW, et al. Code ICH: A Call to Action. *Stroke.* 2024;55(2):494-505. doi: 10.1161/STROKEAHA.123.043033.
8. Al-Shahi Salman R, Frantzas J, Lee RJ, et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. *Lancet Neurol.* 2018;17(10):885-94. doi: 10.1016/S1474-4422(18)30253-9.
9. Brouwers HB, Chang Y, Falcone GJ, et al. Predicting hematoma expansion after primary intracerebral hemorrhage. *JAMA Neurol.* 2014;71(2):158-64. doi: 10.1001/jamaneurol.2013.5433.
10. Prats-Sánchez L, Guasch-Jiménez M, Gich I, et al. Influence of time to admission to a comprehensive stroke centre on the outcome of patients with intracerebral haemorrhage. *Eur Stroke J.* 2020;5(2):115-22. doi: 10.1177/2396987320901616.
11. Parry-Jones AR, Järhult SJ, Kreitzer N, et al. Acute care bundles should be used for patients with intracerebral haemorrhage: An expert consensus statement. *Eur Stroke J.* 2024;9(2):295-302. doi: 10.1177/23969873231220235.
12. Cordonnier C. From Nihilism to Optimism: Bringing a Community to Action. *Stroke.* 2024;55(11):2723-5. doi: 10.1161/STROKEAHA.124.044295.
13. Parry-Jones AR, Sammut-Powell C, Paroutoglou K, et al. An Intracerebral Hemorrhage Care Bundle Is Associated with Lower Case Fatality. *Ann Neurol.* 2019;86(4):495-503. doi: 10.1002/ana.25546.
14. Marti-Fabregas J, Ramos-Pachón A, Prats-Sanchez L, et al; HIC-CAT investigators. Influence of Hospital Type on Outcomes of Patients With Acute Spontaneous Intracerebral Hemorrhage: A Population-Based Study. *Neurology.* 2024;103(2):e209539. doi: 10.1212/WNL.0000000000209539.

15. Steiner T, Al-Shahi Salman R, Beer R, et al; European Stroke Organisation. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. *Int J Stroke*. 2014;9(7):840-55. doi: 10.1111/ijls.12309.
16. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2015;46(7):2032-60. doi: 10.1161/STR.0000000000000069.
17. von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Lancet*. 2007;370(9596):1453-57. doi: 10.1016/S0140-6736(07)61602-X
18. Fernández Sanz A, Ruíz Serrano J, Tejada Meza H, Marta Moreno J. Validation of the Spanish-language version of the simplified modified Rankin Scale telephone questionnaire. *Neurologia (Engl Ed)*. 2022;37(4):271-6. doi: 10.1016/j.nrleng.2019.03.019.
19. Rodriguez-Luna D, Pancorbo O, Llull L, et al; RAINS Study Group. Effects of Achieving Rapid, Intensive, and Sustained Blood Pressure Reduction in Intracerebral Hemorrhage Expansion and Functional Outcome. *Neurology*. 2024;102(9):e209244. doi: 10.1212/WNL.0000000000209244.
20. Sheth KN, Solomon N, Alhanti B, et al. Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage. *JAMA Neurol*. 2024;81(4):36-72. doi: 10.1001/jamaneurol.2024.0221.
21. Pradilla G, Ratcliff JJ, Hall AJ, et al; ENRICH Trial Investigators. Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage. *N Engl J Med*. 2024;390(14):1277-89. doi: 10.1056/NEJMoa2308440.
22. Lund UH, Stoinska-Schneider A, Larsen K, et al. Cost-Effectiveness of Mobile Stroke Unit Care in Norway. *Stroke*. 2022;53(10):3173-81. doi: 10.1161/STROKEAHA.121.037491.
23. Behrndtz A, Blauenfeldt RA, Johnsen SP, et al; TRIAGE-STROKE Trial Investigators. Transport Strategy in Patients With Suspected Acute Large Vessel Occlusion Stroke: TRIAGE-STROKE, a Randomized Clinical Trial. *Stroke*. 2023;54(11):2714-23. doi: 10.1161/STROKEAHA.123.043875.
24. Ramos-Pachón A, Rodríguez-Luna D, Martí-Fàbregas J, et al; RACECAT Trial Investigators. Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage: A Secondary Analysis of the RACECAT Randomized Clinical Trial. *JAMA Neurol*. 2023;80(10):1028-36. doi: 10.1001/jamaneurol.2023.2754.
25. Mrochen A, Song Y, Harders V, Sembill JA, Sprügel MI, Hock S, et al. Influence of bundled care treatment on functional outcome in patients with intracerebral hemorrhage. *Front Neurol*. 2024;15:1357815. doi: 10.3389/fneur.2024.1357815.
26. Colantuono P, D'Anna L, Foschi M, Adipietro M, Lancia S, Mammarella L, et al. How far are we from bringing intensive care bundle for intracerebral hemorrhage into the real-world setting? A 5-year population based-study. *Neurol Sci*. 2025. doi: 10.1007/s10072-025-08113-x.

FIGURE LEGENDS

Figure 1. *Study flowchart showing the inclusion and exclusion of patients from the HIC-CAT registry.*

HIC-CAT: Registry of patients with Spontaneous Acute Intracerebral Hemorrhage in Catalonia; ICH:intracerebral hemorrhage; IVH: intraventricular hemorrhage; mRS: modified Rankin Scale; OTA: symptom onset-to-first hospital admission.

† Data for key variables missing from the final HIC-CAT Database. Following a complete-case analysis approach and given the low proportion of missing data, these patients (n=101, 5.5%) were excluded from the multivariable analysis.

Figure 2. *Interaction between OTA time and CBP achievement. Predicted probability of favorable outcome (mRS 0-3) according to OTA time, stratified by CBP achievement status.*

CBP: care bundle protocol; mRS: modified Rankin Scale; OTA: symptom onset to hospital admission.

Figure 3. *Forest plot showing the effect of CBP achievement on 3-month functional outcome (mRS 0-3), stratified by time intervals. The model was adjusted for age (years), baseline mRS score, NIHSS score on admission, ICH volume (mL), presence of intraventricular hemorrhage (IVH), and infratentorial location.*

aOR >1 indicates increased odds of favorable outcome (mRS 0-3 at 3 months)

Table 1. Patients characteristics stratified by OTA time.

Variables	All (n=1821)	OTA ≤6 hours (n=1294)	OTA >6 hours (n=527)	p value
Age, mean (SD), [n=1821]	70 (14)	69 (14)	73 (13)	<0.001
Women, n (%), [n =1819]	687 (37.8)	476 (36.8)	211 (40.0)	0.202
Baseline mRS score, median (IQR), [n=1821]	0 (0-1)	0 (0-1)	0 (0-2)	<0.001
Unknown ICH onset time, n (%), [n=1821]	616 (33.8)	227 (17.6)	389 (73.8)	<0.001
Admission-to-CT, min, median (IQR), [n=1821]	25 (15-45)	22 (14-37)	34 (20-97)	<0.001
Initial admission to CSC, n (%) [n=1821]	1219 (66.9)	867 (67.0)	352 (66.8)	0.932
Inter-hospital transfer, n (%) [n=1821]	302 (16.6)	198 (15.3)	104 (19.7)	0.021
GCS, median (IQR), [n=1716]	15 (11-15)	14 (10-15)	15 (13-15)	<0.001
NIHSS, median (IQR), [n=1821]	13 (5-21)	14 (6-22)	9 (4-19)	<0.001
ICH volume, mL, median (IQR) [n=1729]	18 (6-45)	18 (6-45)	16 (5-43)	0.284
IVH component, n (%), [n=1759]	703 (40.0)	513 (41.1)	190 (37.2)	0.127
Blood pressure on admission, mmHg, median (IQR)				
-Systolic [n=1607]	165 (143-190)	167 (145-192)	160 (140-182)	<0.001
-Diastolic [n=1585]	89 (77-100)	90 (78-103)	85 (75-98)	<0.001
Body temperature, °C, median (IQR), [n=1109]	36 (35.9-36.5)	36.0 (35.9-36.4)	36.1 (36.0-36.5)	<0.001
O ₂ pulse oximetry, %, median (IQR), [n=1220]	97 (95-99)	97 (95-99)	97 (95-99)	0.822
Prior medical history, n (%)				
-Hypertension [n=1654]	1233 (74.5)	886 (75.7)	347 (71.8)	0.105
-Diabetes mellitus [n=1662]	416 (25.0)	289 (24.5)	127 (26.3)	0.446
-Previous ischemic stroke [n=1618]	197 (12.2)	135 (11.8)	62 (13.1)	0.474
-Previous ICH [n=1563]	114 (7.3)	70 (6.4)	44 (9.5)	0.032
-Ischemic heart disease [n=1664]	181 (10.9)	113 (9.6)	68 (14.1)	0.007
-Antiplatelet use [n=1596]	348 (21.8)	247 (21.9)	101 (21.6)	0.912
-Oral anticoagulant use [n=1674]	322 (19.2)	214 (18.0)	108 (22.2)	0.047
ICH etiology, n (%) [n=1705]				<0.001
-Hypertension	956 (56.1)	720 (59.7)	236 (47.4)	
-Amyloid angiopathy	247 (14.5)	148 (12.3)	99 (19.9)	
-Oral anticoagulants	170 (10.0)	114 (9.4)	56 (11.2)	
-Malformation	77 (4.5)	55 (4.6)	22 (4.4)	
-Other	75 (4.4)	46 (3.8)	29 (5.8)	
-Unknown	180 (10.6)	124 (10.3)	56 (11.2)	
Location, n (%) [n=1751]				<0.001
-Deep (hemisphere)	906 (51.7)	684 (55.0)	222 (43.7)	
-Lobar (hemisphere)	655 (37.1)	426 (34.3)	229 (45.1)	
-Infratentorial	190 (10.9)	133 (10.7)	57 (11.2)	
CBP achievement, n (%)				
-Full achievement [n=1821]	504 (27.7)	342 (26.4)	162 (30.7)	0.062
-Glycemia <150mg/dL 0-24h [n=1271]	1007 (79.2)	714 (79.6)	293 (78.3)	0.615
-Body temperature <37.5°C 0-24h [n=1363]	1252 (91.9)	887 (92.5)	365 (90.3)	0.186
-O ₂ pulse oximetry >92% 0-24h [n=1368]	1249 (91.3)	869 (90.4)	380 (93.4)	0.078
-Blood pressure <140/90mmHg 0-24h [n=1420]	719 (50.6)	486 (48.7)	233 (55.2)	0.025
-Blood pressure medication first 24h [n=1508]	1144 (75.9)	811 (76.7)	333 (73.8)	0.230
-Anticoagulation reversal [n=320]	248 (77.5)	163 (76.9)	85 (78.7)	0.713
Any neurosurgery†, n (%), [n=707]	170 (24.0)	131 (25.1)	39 (21.0)	0.253
-Hematoma evacuation	93 (13.1)	71 (13.6)	22 (11.8)	0.539
-Decompressive craniectomy	60 (9.0)	46 (9.4)	14 (7.8)	0.332
-External ventricular drainage	107 (15.1)	83 (15.9)	24 (12.9)	0.530
Mechanical ventilation, n (%) [n=1558]	321 (21.1)	93 (18.8)	236 (22.2)	0.131
Stroke unit admission, n (%) [n=1744]	1098 (63.0)	745 (60.3)	353 (69.5)	<0.001
ICU admission, n (%) [n=1737]	391 (22.5)	317 (25.8)	74 (14.6)	<0.001
WoC <24h, n (%), [n=1695]	355 (20.9)	257 (21.4)	98 (19.8)	0.456

CBP: care bundle protocol; CSC: Comprehensive Stroke Center; CT: computed tomography; GCS: Glasgow Coma Scale; ICH: intracerebral hemorrhage; IVH: intraventricular hemorrhage; ICU: intensive care unit; IQR: interquartile range; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; OTA: symptom onset to hospital admission; SD: standard deviation; WoC: withdrawal of care. †Any neurosurgery: external ventricular drainage, decompressive craniectomy, and/or hematoma evacuation.

Table 2. Multivariable logistic regression analysis for variables associated with favorable (mRS ≤ 3) outcomes at 3 months.

Variables	aOR	95% CI	p value
Age (years)	0.96	0.95 – 0.97	<0.001
Baseline mRS score	0.67	0.58 – 0.76	<0.001
NIHSS score on admission	0.1	0.89 – 0.92	<0.001
ICH volume on admission (mL)	0.99	0.98 – 0.99	<0.001
IVH component on admission	0.64	0.49 – 0.84	0.001
Infratentorial location	0.62	0.48 – 0.92	0.019
OTA time (hours)	1.04	1.02 – 1.06	0.001
CBP achievement*	1.66	1.29 – 2.15	<0.001

aOR: adjusted odds ratio; CBP: care bundle protocol; CI: confidence interval; ICH: intracerebral hemorrhage; IVH: intraventricular hemorrhage; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; OTA: symptom onset to hospital admission. *CBP achievement is defined as control, in the first 24h according to pre-specified goals, of blood pressure, glycemia, body temperature, and blood oxygen saturation, and anticoagulation reversal if required. aOR >1 indicates increased odds of a favorable outcome (mRS ≤ 3 at 3 months).

Table 3. Patients characteristics stratified by CBP achievement


Variables	All (n=1821)	CBP achieved (n=504)	CBP not achieved (n=1217)	p value
Age, mean (SD), [n=1821]	70 (14)	68 (15)	71 (14)	<0.001
Women, n (%), [n =1819]	687 (37.8)	187 (37.1)	500 (38.0)	0.717
Baseline mRS score, median (IQR), [n=1821]	0 (0-1)	0 (0-1)	0 (0-1)	0.518
Unknown ICH onset time, n (%), [n=1821]	616 (33.8)	146 (32.9)	450 (34.1)	0.285
Onset-to-admission, min, median (IQR), [n=1821]	145 (71-442)	173 (75-493)	132 (69-414)	0.025
Admission-to-CT, min, median (IQR), [n=1821]	25 (15-45)	25 (15-52)	24 (15-43)	0.095
Initial admission to CSC, n (%) [n=1821]	1219 (66.9)	382 (75.8)	837 (63.6)	<0.001
Inter-hospital transfer, n (%) [n=1821]	302 (16.6)	78 (15.5)	224 (17.0)	0.432
GCS, median (IQR), [n=1716]	15 (11-15)	15 (13-15)	14 (9-15)	<0.001
NIHSS, median (IQR), [n=1821]	13 (5-21)	9 (4-17)	15 (6-22)	<0.001
ICH volume, mL, median (IQR) [n=1729]	18 (6-45)	13 (5-30)	20 (6-56)	<0.001
IVH component, n (%), [n=1759]	703 (40.0)	155 (30.8)	548 (43.6)	<0.001
Blood pressure on admission, mmHg, median (IQR)				
-Systolic [n=1607]	165 (143-190)	154 (136-176)	170 (148-194)	<0.001
-Diastolic [n=1585]	89 (77-100)	90 (78-104)	84 (74-95)	<0.001
Body temperature, °C, median (IQR), [n=1109]	36 (35.9-36.5)	36 (36.0-36.5)	36 (35.8-36.4)	0.027
O ₂ pulse oximetry, %, median (IQR), [n=1220]	97 (95-99)	97 (95-99)	97 (96-99)	0.110
Prior medical history, n (%)				
-Hypertension [n=1654]	1233 (74.5)	330 (67.1)	903 (77.7)	<0.001
-Diabetes mellitus [n=1662]	416 (25.0)	94 (19.0)	322 (27.6)	<0.001
-Previous ischemic stroke [n=1618]	197 (12.2)	60 (12.1)	137 (12.2)	0.981
-Previous ICH [n=1563]	114 (7.3)	44 (8.9)	70 (6.5)	0.089
-Ischemic heart disease [n=1664]	181 (10.9)	48 (9.67)	133 (11.4)	0.314
-Antiplatelet use [n=1596]	348 (21.8)	101 (20.5)	247 (22.4)	0.394
-Oral anticoagulant use [n=1674]	322 (19.2)	79 (15.7)	243 (20.8)	0.016
ICH etiology, n (%) [n=1705]				<0.001
-Hypertension	956 (56.1)	262 (52.0)	694 (57.8)	
-Amyloid angiopathy	247 (14.5)	90 (17.9)	157 (13.1)	
-Oral anticoagulants	170 (10.0)	25 (5.0)	145 (12.1)	
-Malformation	77 (4.5)	34 (6.7)	43 (3.6)	
-Other	75 (4.4)	27 (5.4)	48 (4.0)	
-Unknown	180 (10.6)	66 (13.1)	114 (9.5)	
Location, n (%) [n=1751]				0.186
-Deep (hemisphere)	906 (51.7)	253 (50.2)	623 (52.4)	
-Lobar (hemisphere)	655 (37.1)	198 (39.3)	457 (36.6)	
-Infratentorial	190 (10.9)	53 (10.5)	137 (11.0)	
Any neurosurgery†, n (%), [n= 707]	170 (24.0)	57 (32.2)	113 (21.4)	0.004
-Hematoma evacuation	93 (13.1)	35 (19.7)	58 (10.9)	0.003
-Decompressive craniectomy	60 (9.0)	26 (14.7)	34 (6.9)	0.002
-External ventricular drainage	107 (15.1)	34 (19.1)	73 (13.8)	0.084
Stroke unit admission, n (%) [n=1744]	1098 (63.0)	367 (73.4)	731 (58.8)	<0.001
ICU admission, n (%) [n=1737]	391 (22.5)	93 (18.7)	298 (24.1)	0.015
WoC <24h, n (%), [n=1695]	355 (20.9)	38 (7.5)	317 (26.6)	<0.001

CBP: care bundle protocol; CSC: Comprehensive Stroke Center; CT: computed tomography; GCS: Glasgow Coma Scale; ICH: intracerebral hemorrhage; IVH: intraventricular hemorrhage; ICU: intensive care unit; IQR: interquartile range; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; SD: standard deviation; WoC: withdrawal of care. † Any neurosurgery: external ventricular drainage, decompressive craniectomy, and/or hematoma evacuation.

Table 4. Multivariable logistic regression analysis for variables associated with a favorable (mRS ≤ 3) outcome at 3 months in patients who achieved CBP goals (n=504).

Variables	aOR	95% CI	p value
Age (years)	0.96	0.94 – 0.97	<0.001
Baseline mRS score	0.61	0.48 – 0.77	<0.001
NIHSS score on admission	0.91	0.88 – 0.93	<0.001
ICH volume on admission (mL)	0.98	0.97 – 0.99	<0.001
IVH component on admission	0.63	0.39 – 1.03	0.065
Infratentorial location	0.60	0.29 – 1.24	0.167
OTA time (hours)	1.01	0.97 – 1.05	0.570

aOR, adjusted odds ratio; CBP: care bundle protocol; CI, confidence interval; ICH: Intracerebral hemorrhage; IVH, intraventricular hemorrhage; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OTA: symptom onset to hospital admission. aOR >1 indicates increased odds of favorable outcome (mRS ≤ 3 at 3 months).



Care Bundle achievement





No



Yes

Probability of 3-month mRS score 0-3





eTable 1. Patients characteristics according to mRS at 3 months.

Variables	All (n=1821)	3-month mRS≤3 (n=704)	3-month mRS>3 (n=1117)	p value
Age, mean (SD), [n=1821]	70 (14)	66 (14)	73 (13)	<0.001
Women, n (%), [n =1819]	687 (37.8)	257 (36.6)	430 (38.5)	0.398
Baseline mRS score, median (IQR), [n=1821]	0 (0-1)	0 (0-1)	0 (0-2)	<0.001
Unknown ICH onset time, n (%), [n=1821]	616 (33.8)	201 (28.5)	415 (37.1)	<0.001
Onset-to-admission, min, median (IQR), [n=1821]	145 (71-443)	172 (76-517)	125 (67-384)	<0.001
Admission-to-CT, min, median (IQR), [n=1821]	25 (15-45)	28 (17-73)	23 (15-38)	<0.001
Initial admission to CSC, n (%) [n=1821]	1219 (66.9)	435 (61.8)	784 (70.2)	<0.001
Inter-hospital transfer, n (%) [n=1821]	302 (16.6)	157 (22.3)	145 (13.0)	<0.001
GCS score, median (IQR), [n=1716]	15 (11-15)	15 (14-15)	14 (8-15)	<0.001
NIHSS score, median (IQR), [n=1821]	13 (5-21)	6 (3-12)	18 (11-24)	<0.001
ICH volume, mL, median (IQR) [n=1729]	18 (6-45)	7 (3-18)	26 (10-68)	<0.001
IVH component, n (%), [n=1759]	703 (40.0)	161 (23.8)	542 (50.0)	<0.001
Blood pressure on admission, mmHg, median (IQR)				
-Systolic [n=1607]	165 (143-190)	162 (141-185)	167 (144-193)	0.009
-Diastolic [n=1585]	89 (77-100)	88 (77-100)	89 (76-102)	0.320
Body temperature, °C, median (IQR), [n=1109]	36 (35.9-36.5)	36.0 (35.8-36.4)	36.0 (36.0-36.5)	0.057
O ₂ pulse oximetry, %, median (IQR), [n=1220]	97 (95-99)	97 (96-99)	97 (95-99)	0.307
Prior medical history, n (%)				
-Hypertension [n=1654]	1233 (74.5)	466 (71.5)	767 (76.5)	0.021
-Diabetes Mellitus [n=1662]	416 (25.0)	141 (21.7)	275 (27.2)	0.011
-Previous ischemic stroke [n=1618]	197 (12.2)	59 (9.3)	138 (14.0)	0.004
-Previous ICH [n=1563]	114 (7.3)	43 (7.0)	71 (7.5)	0.680
-Ischemic heart disease [n=1664]	181 (10.9)	59 (9.0)	122 (12.1)	0.055
-Antiplatelet use [n=1596]	348 (21.8)	116 (18.4)	232 (24.0)	0.007
-Oral anticoagulant use [n=1674]	322 (19.2)	79 (12.1)	243 (23.8)	<0.001
ICH etiology, n (%) [n=1705]				<0.001
-Hypertension	956 (56.1)	388 (59.1)	568 (54.2)	
-Amyloid angiopathy	247 (14.5)	91 (13.9)	156 (14.9)	
-Oral anticoagulants	170 (10.0)	35 (5.3)	135 (12.9)	
-Malformation	77 (4.5)	43 (6.5)	34 (3.2)	
-Other	75 (4.4)	21 (3.2)	54 (5.1)	
-Unknown	180 (10.6)	79 (12.0)	101 (9.6)	
Location, n (%) [n=1751]				<0.001
-Deep (hemisphere)	906 (51.7)	361 (53.6)	545 (50.6)	
-Lobar (hemisphere)	655 (37.1)	240 (35.6)	415 (38.5)	
-Infratentorial	190 (10.9)	73 (10.8)	117 (10.9)	
CBP achievement, n (%)				
-Full achievement [n=1821]	504 (27.7)	270 (38.4)	234 (20.9)	<0.001
-Glycemia <150mg/dl 0-24h [n=1271]	1007 (79.2)	472 (87.9)	535 (72.9)	<0.001
-Body temperature <37.5°C 0-24h [n=1363]	1252 (91.9)	546 (96.1)	706 (88.8)	<0.001
-O ₂ pulse oximetry >92% 0-24h [n=1368]	1249 (91.3)	548 (97.2)	701 (87.2)	<0.001
-Blood pressure <140/90mmHg 0-24h [n=1420]	719 (50.6)	327 (56.3)	392 (46.7)	<0.001
-Blood pressure medication first 24h [n=1508]	1144 (75.9)	452 (76.7)	692 (75.3)	0.523
-Anticoagulation reversal [n=320]	248 (77.5)	62 (78.5)	186 (77.2)	0.810
Any neurosurgery†, n (%), [n= 707]	170 (24.0)	44 (24.2)	126 (24.0)	0.962
-Hematoma evacuation	93 (13.1)	25 (13.7)	68 (13.0)	0.807
-Decompressive craniectomy	60 (9.0)	14 (8.3)	46 (9.2)	0.739
-External ventricular drainage	107 (15.1)	24 (13.1)	83 (15.8)	0.386
Stroke unit admission, n (%) [n=1744]	1098 (63.0)	547 (81.0)	551 (51.5)	<0.001
ICU admission, n (%) [n=1737]	391 (22.5)	84 (12.6)	307 (28.7)	<0.001
WoC <24h, n (%), [n=1695]	355 (20.9)	39 (6.0)	316 (30.2)	<0.001

CBP: care bundle protocol; CSC: Comprehensive Stroke Center; CT: computed tomography; GCS: Glasgow Coma Scale; ICH: intracerebral hemorrhage; IVH: intraventricular hemorrhage; ICU: intensive care unit; IQR: interquartile range; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; SD: standard deviation; WoC: withdrawal of care. † Any neurosurgery: external ventricular drainage, decompressive craniectomy, and/or hematoma evacuation.

eTable 2. Multivariable logistic regression models for the association between each individual CBP component and favorable functional outcome (mRS ≤3) at 3 months.

Intervention	aOR	95% CI	p value
Model 1 (glycemia <150mg/dL)	1.89	1.30-2.76	0.001
Model 2 (body temperature <37.5°C)	1.96	1.10-3.49	0.022
Model 3 (O ₂ pulse oximetry >92%)	2.70	1.44-5.08	0.002
Model 4 (blood pressure <140/90mmHg)	1.31	1.01-1.71	0.043
Model 5 (anticoagulation reversal)	0.73	0.36-1.50	0.390

Each model includes only one CBP component (as indicated in parentheses) and is adjusted for the same covariates used in the final multivariable model: age (years), baseline mRS score, NIHSS score on admission, ICH volume on admission (mL), IVH component on admission, infratentorial location, and onset-to-admission (OTA) time (hours).